<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460319</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101152</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The SARS-CoV-2 virus continuously acquires mutations, leading to the emergence of new variants. Notably, the effectiveness of global vaccination efforts has significantly declined with the rise and spread of the B.1.1.529 (Omicron) variant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study used virological, immunological and histological research methods, as well as methods of working with laboratory animals. In this study, we evaluated the Gam-COVID-Vac (Sputnik V), an adenoviral vaccine developed by the N.F. Gamaleya National Research Center for Epidemiology and Microbiology, and conducted experiments on hemizygous K18-ACE2-transgenic F1 mice. The variants studied included B.1.1.1, B.1.1.7, B.1.351, B.1.1.28/P.1, B.1.617.2, and B.1.1.529 BA.5.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our findings demonstrate that the Sputnik V vaccine elicits a robust humoral and cellular immune response, effectively protecting vaccinated animals from challenges posed by various SARS-CoV-2 variants. However, we observed a notable reduction in vaccine efficacy against the B.1.1.529 (Omicron BA.5) variant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results indicate that ongoing monitoring of emerging mutations is crucial to assess vaccine efficacy against new SARS-CoV-2 variants to identify those with pandemic potential. If protective efficacy declines, it will be imperative to develop new vaccines tailored to current variants of the virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dolzhikova</LastName><ForeName>Inna V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tukhvatulin</LastName><ForeName>Amir I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0001-8506-2339</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grousova</LastName><ForeName>Daria M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3299-4818</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorkov</LastName><ForeName>Ilya D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komyakova</LastName><ForeName>Marina E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilyukhina</LastName><ForeName>Anna A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovyrshina</LastName><ForeName>Anna V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelkov</LastName><ForeName>Artem Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botikov</LastName><ForeName>Andrey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samokhvalova</LastName><ForeName>Ekaterina G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reshetnikov</LastName><ForeName>Dmitrii A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0003-3851-8959</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siniavin</LastName><ForeName>Andrey E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0001-7576-2059</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savina</LastName><ForeName>Daria M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-2228-3406</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcheblyakov</LastName><ForeName>Dmitrii V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izhaeva</LastName><ForeName>Fatima M</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0002-4110-3941</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzharullaeva</LastName><ForeName>Alina S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erokhova</LastName><ForeName>Alina S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozharovskaya</LastName><ForeName>Tatiana A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zrelkin</LastName><ForeName>Denis I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldovskaya</LastName><ForeName>Polina P</ForeName><Initials>PP</Initials><Identifier Source="ORCID">0009-0000-1965-0482</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semikhin</LastName><ForeName>Alexander S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zubkova</LastName><ForeName>Olga V</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedorubov</LastName><ForeName>Andrey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Federal State Autonomous Educational Institution of Higher Education "I.M. Sechenov First Moscow State Medical University" (Sechenov University), Ministry of Health, Russian Federation, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gushchin</LastName><ForeName>Vladimir A</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0002-9397-3762</Identifier><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naroditsky</LastName><ForeName>Boris S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logunov</LastName><ForeName>Denis Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gintsburg</LastName><ForeName>Alexander L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya", Ministry of Health, Russian Federation, 123098 Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Federal State Autonomous Educational Institution of Higher Education "I.M. Sechenov First Moscow State Medical University" (Sechenov University), Ministry of Health, Russian Federation, 119991 Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">cross-protection</Keyword><Keyword MajorTopicYN="N">hACE2-transgenic mice</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">vector vaccine</Keyword></KeywordList><CoiStatement>I.V.D., A.I.T., D.M.G., A.G.B., F.M.I., A.S.D., A.S.E., O.P., T.A.O., A.S.S., O.V.Z., D.V.S., D.Y.L., B.S.N. and G.A.L. report patents for a Sputnik V pharmaceutical agent, and its method of use to prevent COVID-19. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460319</ArticleId><ArticleId IdType="pmc">PMC11512357</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101152</ArticleId><ArticleId IdType="pii">vaccines12101152</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  COVID-19 Public Health Emergency of International Concern (PHEIC) Global Research and Innovation Forum.  [(accessed on 3 October 2024)].  Available online:  https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum.</Citation></Reference><Reference><Citation>World Health Organization  WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020.  [(accessed on 3 October 2024)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</Citation></Reference><Reference><Citation>World Health Organization  WHO COVID-19 Dashboard.  [(accessed on 3 October 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases?n=c.</Citation></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e6. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z., Deng Y.Q., Ye Q., Cao L., Sun C.Y., Fan C., Huang W., Sun S., Sun Y., Zhu L., et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369:1505–1509. doi: 10.1126/science.abc5881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5881</ArticleId><ArticleId IdType="pmc">PMC7402622</ArticleId><ArticleId IdType="pubmed">32703908</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J., Le Bas A., Ruza R.R., Duyvesteyn H.M.E., Mikolajek H., Malinauskas T., Tan T.K., Rijal P., Dumoux M., Ward P.N., et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 2020;27:846–854. doi: 10.1038/s41594-020-0469-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0469-6</ArticleId><ArticleId IdType="pubmed">32661423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Wang Y., Jin Y., Zhu Y., Wu Y., Li C., Kong Y., Song W., Tian X., Zhan W., et al. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduct. Target. Ther. 2021;6:378. doi: 10.1038/s41392-021-00810-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00810-1</ArticleId><ArticleId IdType="pmc">PMC8564274</ArticleId><ArticleId IdType="pubmed">34732694</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandker S.S., Godman B., Jawad M.I., Meghla B.A., Tisha T.A., Khondoker M.U., Haq M.A., Charan J., Talukder A.A., Azmuda N., et al. A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines. 2021;9:1387. doi: 10.3390/vaccines9121387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121387</ArticleId><ArticleId IdType="pmc">PMC8708628</ArticleId><ArticleId IdType="pubmed">34960133</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis A.I., Ghany S., Gilkes T., Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad. Med. J. 2022;98:389–394. doi: 10.1136/postgradmedj-2021-140654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-140654</ArticleId><ArticleId IdType="pubmed">37066438</ArticleId></ArticleIdList></Reference><Reference><Citation>Magazine N., Zhang T., Wu Y., McGee M.C., Veggiani G., Huang W. Mutations and Evolution of the SARS-CoV-2 Spike Protein. Viruses. 2022;14:640. doi: 10.3390/v14030640.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030640</ArticleId><ArticleId IdType="pmc">PMC8949778</ArticleId><ArticleId IdType="pubmed">35337047</ArticleId></ArticleIdList></Reference><Reference><Citation>Palyanov A.Y., Palyanova N.V. On the space of SARS-CoV-2 genetic sequence variants. Vavilovskii Zhurnal Genet. Selektsii. 2023;27:839–850. doi: 10.18699/VJGB-23-97.</Citation><ArticleIdList><ArticleId IdType="doi">10.18699/VJGB-23-97</ArticleId><ArticleId IdType="pmc">PMC10777302</ArticleId><ArticleId IdType="pubmed">38213712</ArticleId></ArticleIdList></Reference><Reference><Citation>Laidlaw B.J., Ellebedy A.H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 2022;22:7–18. doi: 10.1038/s41577-021-00657-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00657-1</ArticleId><ArticleId IdType="pmc">PMC8647067</ArticleId><ArticleId IdType="pubmed">34873279</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., COVID-19 Genomics UK Consortium. Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding K., Jiang W., Xiong C., Lei M. Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic? Immun. Inflamm. Dis. 2022;10:e606. doi: 10.1002/iid3.606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.606</ArticleId><ArticleId IdType="pmc">PMC8962637</ArticleId><ArticleId IdType="pubmed">35349754</ArticleId></ArticleIdList></Reference><Reference><Citation>Fall A., Eldesouki R.E., Sachithanandham J., Morris C.P., Norton J.M., Gaston D.C., Forman M., Abdullah O., Gallagher N., Li M., et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads. EBioMedicine. 2022;79:104008. doi: 10.1016/j.ebiom.2022.104008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104008</ArticleId><ArticleId IdType="pmc">PMC9020587</ArticleId><ArticleId IdType="pubmed">35460989</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H., Moir M., Everatt J., Giovanetti M., Scheepers C., Wilkinson E., Subramoney K., Makatini Z., Moyo S., Amoako D.G., et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. 2022;28:1785–1790. doi: 10.1038/s41591-022-01911-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01911-2</ArticleId><ArticleId IdType="pmc">PMC9499863</ArticleId><ArticleId IdType="pubmed">35760080</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., Song W., Xiao T., Wang L., Du S., Wang J., Li Q., Chen X., et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi: 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Karuppanan K., Subramaniam G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. J. Med. Virol. 2022;94:4780–4791. doi: 10.1002/jmv.27927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27927</ArticleId><ArticleId IdType="pmc">PMC9347785</ArticleId><ArticleId IdType="pubmed">35680610</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhatib M., Salpini R., Carioti L., Ambrosio F.A., D’Anna S., Duca L., Costa G., Bellocchi M.C., Piermatteo L., Artese A., et al. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile. Microbiol. Spectr. 2022;10:e0273221. doi: 10.1128/spectrum.02732-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02732-21</ArticleId><ArticleId IdType="pmc">PMC9045195</ArticleId><ArticleId IdType="pubmed">35352942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeel A., Moatasim Y., Fahim M., Bahaaeldin H., El-Shesheny R., Roshdy W.H., Kamel M.N., Shawky S., Gomaa M., Naguib A., et al. Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020–2022: Insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality. BMC Infect. Dis. 2023;23:542. doi: 10.1186/s12879-023-08527-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08527-y</ArticleId><ArticleId IdType="pmc">PMC10439637</ArticleId><ArticleId IdType="pubmed">37596534</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvavinayagam S.T., Yong Y.K., Joseph N., Hemashree K., Tan H.Y., Zhang Y., Rajeshkumar M., Kumaresan A., Kalpana R., Kalaivani V., et al. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. Front. Public Health. 2022;10:1018399. doi: 10.3389/fpubh.2022.1018399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.1018399</ArticleId><ArticleId IdType="pmc">PMC9540788</ArticleId><ArticleId IdType="pubmed">36211690</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A., Nutalai R., Dijokaite-Guraliuc A., Zhou D., Ginn H.M., Selvaraj M., Liu C., Mentzer A.J., Supasa P., Duyvesteyn H.M.E., et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433.e13. doi: 10.1016/j.cell.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Li X., Zhang L., Wan S., Zhang L., Zhou F. SARS-CoV-2 Omicron variant: Recent progress and future perspectives. Signal Transduct. Target Ther. 2022;7:141. doi: 10.1038/s41392-022-00997-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00997-x</ArticleId><ArticleId IdType="pmc">PMC9047469</ArticleId><ArticleId IdType="pubmed">35484110</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Wang L., Zhu Y., Lu L., Jiang S. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct. Target Ther. 2022;7:241. doi: 10.1038/s41392-022-01105-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01105-9</ArticleId><ArticleId IdType="pmc">PMC9295084</ArticleId><ArticleId IdType="pubmed">35853878</ArticleId></ArticleIdList></Reference><Reference><Citation>GOST 33044-2014. Interstate Standard. Principles of Good Laboratory Practice.  [(accessed on 3 October 2024)].  Available online:  https://protect.gost.ru/document.aspx?control=7&amp;baseC=6&amp;page=6&amp;month=2&amp;year=2023&amp;search=&amp;RegNum=1&amp;DocOnPageCount=15&amp;id=238531.</Citation></Reference><Reference><Citation>Roederer M. Interpretation of cellular proliferation data: Avoid the panglossian. Cytom. A. 2011;79:95–101. doi: 10.1002/cyto.a.21010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.21010</ArticleId><ArticleId IdType="pubmed">21265003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukhvatulin A.I., Gordeychuk I.V., Dolzhikova I.V., Dzharullaeva A.S., Krasina M.E., Bayurova E.O., Grousova D.M., Kovyrshina A.V., Kondrashova A.S., Avdoshina D.V., et al. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerg. Microbes Infect. 2022;11:2229–2247. doi: 10.1080/22221751.2022.2119169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2119169</ArticleId><ArticleId IdType="pmc">PMC9518644</ArticleId><ArticleId IdType="pubmed">36031930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapa D., Grousova D.M., Matusali G., Meschi S., Colavita F., Bettini A., Gramigna G., Francalancia M., Garbuglia A.R., Girardi E., et al. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines. 2022;10:817. doi: 10.3390/vaccines10050817.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050817</ArticleId><ArticleId IdType="pmc">PMC9144866</ArticleId><ArticleId IdType="pubmed">35632574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gushchin V.A., Dolzhikova I.V., Shchetinin A.M., Odintsova A.S., Siniavin A.E., Nikiforova M.A., Pochtovyi A.A., Shidlovskaya E.V., Kuznetsova N.A., Burgasova O.A., et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines. 2021;9:779. doi: 10.3390/vaccines9070779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9070779</ArticleId><ArticleId IdType="pmc">PMC8310330</ArticleId><ArticleId IdType="pubmed">34358195</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann N.P., Miller J., Collier A.Y., Ventura J.D., Yu J., Rowe M., Bondzie E.A., Powers O., Surve N., Hall K., et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 2022;387:86–88. doi: 10.1056/NEJMc2206576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206576</ArticleId><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bormann M., Brochhagen L., Alt M., Otte M., Thümmler L., van de Sand L., Kraiselburd I., Thomas A., Gosch J., Braß P., et al. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5. Front. Immunol. 2023;14:1150667. doi: 10.3389/fimmu.2023.1150667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1150667</ArticleId><ArticleId IdType="pmc">PMC10372796</ArticleId><ArticleId IdType="pubmed">37520539</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice A., Verma M., Shin A., Zakin L., Sieling P., Tanaka S., Adisetiyo H., Taft J., Patel R., Buta S., et al. A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses. bioRxiv. 2020 doi: 10.1101/2020.07.29.227595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.29.227595</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoushtari M., Roohvand F., Salehi-Vaziri M., Arashkia A., Bakhshi H., Azadmanesh K. Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses. Hum. Vaccin. Immunother. 2022;18:2079323. doi: 10.1080/21645515.2022.2079323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2079323</ArticleId><ArticleId IdType="pmc">PMC9481145</ArticleId><ArticleId IdType="pubmed">35714271</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnani S. Th1/Th2 cells. Inflamm. Bowel Dis. 1999;5:285–294. doi: 10.1097/00054725-199911000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00054725-199911000-00009</ArticleId><ArticleId IdType="pubmed">10579123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Iketani S., Nair M.S., Li Z., Mohri H., Wang M., Yu J., Bowen A.D., Chang J.Y., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603–608. doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q.L., Zhang J.W., Wang P.T., Zhang Z.Y. Immune response and evasion mechanisms of major SARS-CoV-2 variants. Iscience. 2022;25:105044. doi: 10.1016/j.isci.2022.105044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105044</ArticleId><ArticleId IdType="pmc">PMC9436868</ArticleId><ArticleId IdType="pubmed">36068846</ArticleId></ArticleIdList></Reference><Reference><Citation>GISAID  Tracking of hCoV-19 Variants.  [(accessed on 3 October 2024)].  Available online:  https://gisaid.org/hcov19-variants.</Citation></Reference><Reference><Citation>Shao W., Chen X., Zheng C., Liu H., Wang G., Zhang B., Li Z., Zhang W. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: A literature review and meta-analysis. Emerg. Microbes Infect. 2022;11:2383–2392. doi: 10.1080/22221751.2022.2122582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2122582</ArticleId><ArticleId IdType="pmc">PMC9542696</ArticleId><ArticleId IdType="pubmed">36069511</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>